EQRx links arms with In­sil­i­co on that two-let­ter buzz­word (AI); De­spite miss in pre­vi­ous­ly treat­ed pa­tients, Ri­bom­ic push­ing eye drug for­ward

An­oth­er deal has been inked in the ar­ti­fi­cial in­tel­li­gence-based drug dis­cov­ery land­scape, and it’s one fea­tur­ing a key play­er tout­ing the two-let­ter buzz­word fre­quent­ly, team­ing up with one of those biotechs claim­ing to be part of the next wave of de­vel­op­ers of low­er-cost drugs.

In­sil­i­co Med­i­cine and EQRx will col­lab­o­rate on up to three tar­gets on de no­vo small mol­e­cule de­sign. Deal terms were kept un­der the hood. The com­pa­nies will use In­sil­i­co’s AI tools in the pre­clin­i­cal stages, and EQRx will han­dle clin­i­cal de­vel­op­ment. The AI play­er can in­vest at var­i­ous points along the clin­i­cal stages, if In­sil­i­co so choos­es, in re­turn for more com­mer­cial­iza­tion prof­its.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER